Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 110, Issue 8, Pages 914-917Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djy012
Keywords
-
Categories
Funding
- Spanish Cancer Association (AECC) Scientific Foundation [GCB14-2170]
- Spanish Ministries of Health
- Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional [PI14/01248]
- Instituto de Salud Carlos III [PI17-01080, CP14/00228]
- Catalan Agency AGAUR [2014 SGR 1331]
- AECC
Ask authors/readers for more resources
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. We present a patient with a lung tumor with an exceptional response to cisplatin/gemcitabine in combination with HSP90i, which nowadays continues with HSP90i maintenance after three years. Whole-exome sequencing of the lung tumor unveiled a BRCA1/2 deficiency mutational signature, and mutation analysis confirmed a germline BRCA1 mutation. The striking efficacy of HSP90i plus chemotherapy vs chemotherapy alone was reproduced in a patient-derived xenograft (PDX) model from a breast cancer patient with a BRCA1 mutation (mean tumor volume [SD], No. of tumors: vehicle 8.38 [7.07] mm(3), n = 3; HSP90i 4.18 [1.93] mm(3), n = 5; cisplatin plus gemcitabine 3.31 [1.95] mm(3), n = 5; cisplatin plus gemcitabine plus HSP90i 0.065 [0.076] mm(3), n = 6). This case and the PDX demonstrate the efficacy for therapeutic inhibition of HSP90 in a BRCA-mutated patient, opening a new potential avenue for better identifying patients who might benefit most from HSP90i.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available